Benzyl 1,5-dioxa-9-azaspiro[5.5]undecane-9-carboxylate | 143656-77-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: Benzyl 1,5-dioxa-9-azaspiro[5.5]undecane-9-carboxylate
• CAS: 143656-77-3
• 化学式: C₁₆H₂₁NO₄
• 分子量: 291.347
• InChiKey: RXBBNTMEDBNQHU-UHFFFAOYSA-N

物化性质

• 沸点：
  434.4±45.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Benzyl 1,5-dioxa-9-azaspiro[5.5]undecane-9-carboxylate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 1,5-二叠氮-9-壬烯[5.5]十一烷
  参考文献：
  名称：

  Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein

  摘要：

  Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-alpha] pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50's of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50's = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.080
• 作为产物：
  描述：

  氯甲酸苄酯 、 1,5-二叠氮-9-壬烯[5.5]十一烷 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以68%的产率得到Benzyl 1,5-dioxa-9-azaspiro[5.5]undecane-9-carboxylate
  参考文献：
  名称：

  HIV Integrase Inhibitors

  摘要：

  这项发明涵盖了公式I的系列双环嘧啶酮化合物，这些化合物抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病有用。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。

  公开号：

  US20070281917A1

文献信息

• HIV integrase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US07897593B2

  公开（公告）日：2011-03-01

  The invention encompasses series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  该发明涵盖了一系列双环嘧啶酮化合物，其化学式为I，可抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物有用于治疗HIV感染和艾滋病。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。
• US7897593B2
  申请人：——

  公开号：US7897593B2

  公开（公告）日：2011-03-01
• [EN] SPIRO-CONDENSED HETEROTRICYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROTRICYCLIQUES SPIRO-CONDENSÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA VIH INTÉGRASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2007143446A1

  公开（公告）日：2007-12-13

  [EN] The invention encompasses series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
  [FR] La présente invention concerne une série de composés de pyrimidinone bicycliques répondant à la formule I qui inhibent la HIV intégrase et empêchent l'intégration virale dans l'ADN humain. De par leur mode d'action, les composés se révèlent utiles pour le traitement de l'infection par le VIH et le traitement du SIDA. L'invention concerne également des compositions pharmaceutiques et des procédés destinés au traitement d'individus infectés par le VIH.
• Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein
  作者：Vincent W.-F. Tai、Dulce Garrido、Daniel J. Price、Andrew Maynard、Jeffrey J. Pouliot、Zhiping Xiong、John W. Seal、Katrina L. Creech、Luz H. Kryn、Todd M. Baughman、Andrew J. Peat

  DOI：10.1016/j.bmcl.2014.03.080

  日期：2014.5

  Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-alpha] pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50's of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50's = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein. (C) 2014 Elsevier Ltd. All rights reserved.
• HIV Integrase Inhibitors
  申请人：Naidu B. Narasimhulu

  公开号：US20070281917A1

  公开（公告）日：2007-12-06

  The invention encompasses series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  这项发明涵盖了公式I的系列双环嘧啶酮化合物，这些化合物抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病有用。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。